Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby

Seeking AlphaNov 23 08:26 ET

TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371

Moomoo NewsNov 19 03:36 ET · Ratings

Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler

Dow JonesNov 18 13:10 ET · Ratings

ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study

Zacks Nov 18 08:35 ET

TD Cowen Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

TipRanksNov 18 07:36 ET · Ratings

Alnylam Pharmaceuticals Announces Interim Phase 1 Data of Nucresiran

TipRanksNov 17 10:00 ET